NewsBenzingaUCB와 바이오젠, 사후 분석 3상 PHOENYCS GO에서 다피롤리주맙 페골 병용 표준 치료가 새로운 TRM-SLE 지표에서 위약 대비 높은 반응률 및 질환 활성도 지속적 저하 효과 확인 UCB와 바이오젠, 사후 분석 3상 PHOENYCS GO에서 다피롤리주맙 페골 병용 표준 치료가 새로운 TRM-SLE 지표에서 위약 대비 높은 반응률 및 질환 활성도 지속적 저하 효과 확인 Benzinga 2026.11.09 06:56 (GMT+0) Open on Benzinga Other news 'China Taps US AI Models To Train Homegrown Rivals As Chip Curbs Bite' - Reuters Exclusive 'Ruined The System'? Pete Buttigieg Pushes Back On Trump's FAA Blame, Demands Accounting for Billions In Modernization Funds After 'Worst FAA Communications Breakdown This Century' A-Share Close: ChiNext Index Down Over 1% After Intraday Reversal, More Than 4,100 Stocks Fall Reported Earlier, Lecanemab Five-Year Clarity AD Data: 36% Lower Relative Risk Of Disease-Stage Progression Vs. ADNI, 62% Of Low-Tau Patients Improved On CDR-SB, Consistent Safety Profile, Per Eisai And Biogen Aytu BioPharma Stock Climbs 44% After-Hours: Here's Why Reported Earlier, MediaCo Holding Q3 EPS $(0.11) Up From $(0.22) YoY, Sales $28.600M Down From $35.398M YoY
'Ruined The System'? Pete Buttigieg Pushes Back On Trump's FAA Blame, Demands Accounting for Billions In Modernization Funds After 'Worst FAA Communications Breakdown This Century'
Reported Earlier, Lecanemab Five-Year Clarity AD Data: 36% Lower Relative Risk Of Disease-Stage Progression Vs. ADNI, 62% Of Low-Tau Patients Improved On CDR-SB, Consistent Safety Profile, Per Eisai And Biogen
Reported Earlier, MediaCo Holding Q3 EPS $(0.11) Up From $(0.22) YoY, Sales $28.600M Down From $35.398M YoY